Phaseline

Companies › Immunophotonics

Immunophotonics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IP-001
Intratumoral immunotherapy agent
–Phase 1Metastatic Solid Tumor; Hepatocellular Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05688280IP-001Phase 1Metastatic Solid TumorOncologyFeb 2025
NCT06526338IP-001Phase 2Hepatocellular CarcinomaOncologyDec 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.